Induced activation in dendritic cells

Patent metadata

Field	Value
Publication number	US-9572835-B2
Application number	US-201514643989-A
Country	US
Kind code	B2
Filing date	Mar 10, 2015
Priority date	Feb 18, 2003
Publication date	Feb 21, 2017
Grant date	Feb 21, 2017

Abstract

The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide.

First claim

What is claimed is:

1. An isolated cell comprising a nucleic acid, wherein the nucleic acid comprises a promoter operably linked to a polynucleotide that encodes a chimeric protein, wherein the chimeric protein comprises
a) a membrane targeting region;
b) a multimeric ligand binding region; and
c) a CD40 polypeptide cytoplasmic region wherein the CD40 polypeptide does not have a functional extracellular domain.

2. The isolated cell of claim 1 , wherein the cell is an antigen presenting cell.

3. The isolated cell of claim 1 , wherein the cell is a dendritic cell.

4. The isolated cell of claim 1 , wherein the membrane targeting region is selected from the group consisting of a myristoylation region, palmitoylation region, prenylation region, and transmembrane sequences of receptors.

5. The isolated cell of claim 1 , wherein the membrane targeting region is a myristoylation region.

6. The isolated cell of claim 1 , wherein the multimeric ligand binding region is selected from the group consisting of FKBP, cyclophilin receptor, the steroid receptor, the tetracycline receptor, heavy chain antibody subunit, light chain antibody subunit, and mutated sequences thereof.

7. The isolated cell of claim 1 , wherein the multimeric ligand binding region comprises an FKBP12 region.

8. The isolated cell of claim 1 , wherein the multimeric ligand binding region comprises FKBP12(V36).

9. The isolated cell of claim 1 , wherein the multimeric ligand binding region comprises tandem copies of an FKBP region.

10. The isolated cell of claim 1 , wherein the multimeric ligand binding region comprises tandem copies of FKBP12(V36).

11. The isolated cell of claim 1 , further comprising a polynucleotide that encodes a tumor antigen.

12. The isolated cell of claim 11 , wherein the tumor antigen is PSMA.

13. A pharmaceutical composition comprising a cell of claim 1 , and a pharmaceutically acceptable buffer.

Assignees

• Baylor College Medicine

Inventors

• Spencer David
• Hanks Brent
• Slawin Kevin

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61K38/1774

  Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules) · CPC title

• C12N2710/10043

  viral genome or elements thereof as genetic vector · CPC title

• C12N9/90

  Isomerases (5.) · CPC title

• C12N9/485

  Exopeptidases (3.4.11-3.4.19) · CPC title